Despite Downward Pressure on Average Selling Prices, Procedural Growth Will Drive Revenues, According to Millennium Research Group

January 18, 2012—Toronto—According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the North American facial injectables market will see strong growth through 2016, despite significant downward pressure on selling prices caused by the entry of new, lower-priced products into the market. Growth will average 11 percent per year, and the market will grow from $844 million in 2011 to more than $1.4 billion in 2016.

Merz Pharmaceuticals, with a strong reputation in Europe, will introduce new products in both the botulinum toxin (BTX) and dermal filler market segments of the North American market. Merz’s BTX product, Xeomin, received Food and Drug Administration (FDA) approval in 2011, adding a third BTX product into a market previously divided between Allergan’s dominant BOTOX and Ipsens’ Dysport products. Merz plans to launch the product in spring 2012. It does not yet have approval in Canada. Additional potential competitors in this market include Mentor (a Johnson & Johnson company) and Prollenium Medical Technologies.

Merz has also received FDA approval for its dermal filler product Belotero Balance in November 2011 and is expected launch Belotero in 2012. This product does not yet have approval in Canada. The dermal filler market includes more competitors than the BTX market does, including Allergan and Medicis Pharmaceutical. Mentor, Contura and Prollenium are also expected to enter the dermal filler market in the near future.

“The approval of both Merz Pharmaceuticals products will have an effect on both the BTX and dermal filler markets,” said MRG Analyst April Lee. “Merz has a reputation for strong price competition and will likely offer them at lower prices than the current leading products. These lower prices will be attractive to both physicians and patients, and will drive down average selling prices overall.”
Despite the poor economy of the past couple of years, patient demand for aesthetic procedures will continue to increase. The affordability of these procedures, in comparison to more invasive procedures such as surgical facelifts, will drive procedural volume through 2016. Total procedures will grow at an average rate of more than twelve percent per year.

Millennium Research Group’s North American Markets for Facial Injectables 2012 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for botulinum toxin (BTX), hyaluronic acid (HA) fillers, and semi- and nonpermanent fillers in the United States and Canada.

Webinar: North American and European Facial Injectable Markets
Join MRG analysts April Lee and Carmen Chan for an analysis of facial injectable markets in North America and Europe, in a free webinar on January 19 at 11 a.m. U.S. Eastern Time. To register for this webinar go to http://mrg.net/News-and-Events/Webinars.aspx.